In its latest quarterly update, Climb Bio, Inc. reported continued progress in clinical-stage development of novel monoclonal antibodies targeting immune-mediated diseases. The lead asset budoprutug is advancing multiple Phase 2 and early-phase trials, supported by orphan drug designation and a strategic focus on subcutaneous formulation development. Alongside CLYM116’s Phase 1 study for IgA nephropathy, the company is expanding its pipeline breadth against a backdrop of significant competition in B-cell targeted therapies. Climb Bio’s financial profile is strong with over $44 million in cash and equivalents and a current ratio exceeding 30, supporting cash runway into 2028 despite ongoing R&D expenses.